MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback